When a biotech sponsor outsources API manufacturing to an Indian CDMO, two regulatory conversations happen simultaneously.
One is about the NDA or IND. The other is about the Drug Master File, the confidential CMC package the manufacturer holds independently with the FDA and EMA.
Most sponsors underestimate how much the second affects the first.
What a Drug Master File Is and Why It Exists
A Drug Master File is a confidential submission to the FDA containing detailed chemistry, manufacturing, and controls information for an API. The manufacturer holds it. The sponsor references it.
The mechanism allows an API manufacturer to support dozens of drug product applications without disclosing proprietary process information to each sponsor. The FDA accesses the DMF only when a sponsor references it in an NDA, ANDA, or IND. Over 21,000 active DMFs are on file with the FDA, and the majority are Type II DMFs covering drug substances and their manufacturing processes.
A Type II DMF follows the CTD S module structure:
- S.1 General properties of the API
- S.2 Manufacture, including the synthetic route, process controls, and critical steps
- S.3 Characterization, covering structure elucidation and impurity identification
- S.4 Specification, including tests, analytical methods, and acceptance criteria
- S.5 Reference standards
- S.6 Container closure system
- S.7 Stability data
Since 2025, eCTD format is mandatory for all DMF submissions to the FDA.
The Letter of Authorization Mechanism
The sponsor does not receive a copy of the DMF. They receive a Letter of Authorization (LOA) from the CDMO, granting the FDA permission to review the DMF in connection with the sponsor’s application.
This creates a dependency CMC teams frequently underestimate. If the CDMO’s DMF has an open deficiency, the FDA cannot complete its review of the DMF section referenced in the sponsor’s application, stalling a review on a problem the sponsor cannot fix.
The same logic applies to amendments. When the CDMO updates the DMF, whether for a process change, a raw material specification update, or an equipment change, the sponsor must be notified. Industry best practice calls for notification within 48 hours of submitting any DMF amendment. Without it, a sponsor can receive an FDA deficiency letter about a change they were never told had happened.
The EU Equivalent: Active Substance Master File
In the EU, the equivalent of a Type II DMF is the Active Substance Master File (ASMF), sometimes called the EDMF. It has two parts:
- Open Part: Non-confidential information shared with the drug product sponsor for inclusion in the marketing authorization dossier
- Restricted Part: Confidential manufacturing process and control data submitted directly to the EMA or national competent authority
Unlike the FDA DMF, the Open Part travels with the sponsor’s dossier, making the sponsor responsible for placing it in the correct CTD module position.
For sponsors targeting both US and EU markets, their Indian CDMO should hold both a Type II DMF with the FDA and an ASMF with the EMA. Managing both with harmonized chemistry data is significantly more efficient than running them independently.
What the FDA Consistently Finds Wrong
The FDA’s SBIA Conference in April 2025 published a summary of the most common Type II DMF deficiencies. The top three categories account for more than 60% of all deficiency letters:
- Incomplete process descriptions in S.2, including missing critical step identification, undefined in-process controls, and absent process flow diagrams
- Inadequate analytical method validation in S.4, where methods do not meet ICH Q2(R2) requirements for specificity, precision, and accuracy
- Insufficient impurity control in S.3 and S.4, including missing structure elucidation for specified impurities and unjustified impurity limits
A deficiency letter adds three to six months to a review timeline. A CDMO with an incomplete DMF is a program risk that only becomes visible when it is already too late to fix quickly.
What Sponsors Must Check Before Referencing a CDMO’s DMF
Before issuing a Letter of Authorization, ask:
- Is the DMF currently adequate? Request confirmation from the CDMO that the DMF has passed FDA’s completeness assessment and has no open deficiencies.
- When was the last annual report submitted? DMF holders must submit annual reports. A lapsed annual report is a common flag in FDA reviews.
- Is the DMF in eCTD format? Non-eCTD submissions are no longer accepted by FDA as of 2025.
- What is the amendment notification process? Get a written commitment on the turnaround time for notifying your team of any DMF amendment before it is submitted.
- Does a parallel ASMF exist for EU submissions? If your program targets European markets, confirm the ASMF is current and that the Open Part is available for your dossier.
How LAXAI Manages DMF and ASMF Submissions
LAXAI’s regulatory support team manages Drug Master File submissions and lifecycle maintenance as part of the CMC service it provides to sponsors.
DMF documentation at LAXAI is built in parallel with process development, not assembled retrospectively. This means the S.2 process descriptions are written by the same team that designed the process, the analytical methods in S.4 are validated in-house under ICH Q2(R2), and the impurity control strategy in S.3 reflects the actual impurity fate and purge analysis done during development.
When a CDMO builds its DMF from a process it developed, not a process it inherited, the documentation quality is materially better. That is the most reliable way to avoid deficiency letters.
Contact LAXAI’s regulatory team to discuss your DMF and ASMF requirements at bd@laxai.com
FAQs
What is the difference between a Type II DMF and an ASMF? A Type II DMF is the US FDA submission, kept confidential from the sponsor. The ASMF is the EU equivalent, divided into an Open Part shared with the sponsor and a Restricted Part submitted directly to the EMA or national authority.
Does the FDA approve a Drug Master File? No. A DMF is reviewed only when referenced in an active application such as an NDA or ANDA. The FDA issues a completeness assessment and may raise deficiencies, but there is no standalone approval.
What is a Letter of Authorization? Issued by the DMF holder to the sponsor, granting the FDA permission to review the DMF in connection with the sponsor’s application. Without a valid LOA, the FDA cannot access the DMF content during review.
What happens if a CDMO updates their DMF without notifying the sponsor? The sponsor may receive an FDA deficiency letter about a change they were unaware of, delaying application review by three to six months. Sponsors should obtain a written amendment notification agreement before referencing the DMF.
